NM_201384.3:c.174+22G>C

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_201384.3(PLEC):​c.174+22G>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.367 in 1,610,558 control chromosomes in the GnomAD database, including 113,874 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.29 ( 7864 hom., cov: 33)
Exomes 𝑓: 0.37 ( 106010 hom. )

Consequence

PLEC
NM_201384.3 intron

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:8

Conservation

PhyloP100: 0.239

Publications

12 publications found
Variant links:
Genes affected
PLEC (HGNC:9069): (plectin) Plectin is a prominent member of an important family of structurally and in part functionally related proteins, termed plakins or cytolinkers, that are capable of interlinking different elements of the cytoskeleton. Plakins, with their multi-domain structure and enormous size, not only play crucial roles in maintaining cell and tissue integrity and orchestrating dynamic changes in cytoarchitecture and cell shape, but also serve as scaffolding platforms for the assembly, positioning, and regulation of signaling complexes (reviewed in PMID: 9701547, 11854008, and 17499243). Plectin is expressed as several protein isoforms in a wide range of cell types and tissues from a single gene located on chromosome 8 in humans (PMID: 8633055, 8698233). Until 2010, this locus was named plectin 1 (symbol PLEC1 in human; Plec1 in mouse and rat) and the gene product had been referred to as "hemidesmosomal protein 1" or "plectin 1, intermediate filament binding 500kDa". These names were superseded by plectin. The plectin gene locus in mouse on chromosome 15 has been analyzed in detail (PMID: 10556294, 14559777), revealing a genomic exon-intron organization with well over 40 exons spanning over 62 kb and an unusual 5' transcript complexity of plectin isoforms. Eleven exons (1-1j) have been identified that alternatively splice directly into a common exon 2 which is the first exon to encode plectin's highly conserved actin binding domain (ABD). Three additional exons (-1, 0a, and 0) splice into an alternative first coding exon (1c), and two additional exons (2alpha and 3alpha) are optionally spliced within the exons encoding the acting binding domain (exons 2-8). Analysis of the human locus has identified eight of the eleven alternative 5' exons found in mouse and rat (PMID: 14672974); exons 1i, 1j and 1h have not been confirmed in human. Furthermore, isoforms lacking the central rod domain encoded by exon 31 have been detected in mouse (PMID:10556294), rat (PMID: 9177781), and human (PMID: 11441066, 10780662, 20052759). The short alternative amino-terminal sequences encoded by the different first exons direct the targeting of the various isoforms to distinct subcellular locations (PMID: 14559777). As the expression of specific plectin isoforms was found to be dependent on cell type (tissue) and stage of development (PMID: 10556294, 12542521, 17389230) it appears that each cell type (tissue) contains a unique set (proportion and composition) of plectin isoforms, as if custom-made for specific requirements of the particular cells. Concordantly, individual isoforms were found to carry out distinct and specific functions (PMID: 14559777, 12542521, 18541706). In 1996, a number of groups reported that patients suffering from epidermolysis bullosa simplex with muscular dystrophy (EBS-MD) lacked plectin expression in skin and muscle tissues due to defects in the plectin gene (PMID: 8698233, 8941634, 8636409, 8894687, 8696340). Two other subtypes of plectin-related EBS have been described: EBS-pyloric atresia (PA) and EBS-Ogna. For reviews of plectin-related diseases see PMID: 15810881, 19945614. Mutations in the plectin gene related to human diseases should be named based on the position in NM_000445 (variant 1, isoform 1c), unless the mutation is located within one of the other alternative first exons, in which case the position in the respective Reference Sequence should be used. [provided by RefSeq, Aug 2011]
PLEC Gene-Disease associations (from GenCC):
  • epidermolysis bullosa simplex
    Inheritance: AD Classification: STRONG Submitted by: G2P
  • epidermolysis bullosa simplex 5A, Ogna type
    Inheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, PanelApp Australia, Genomics England PanelApp
  • autosomal recessive limb-girdle muscular dystrophy type 2Q
    Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, G2P, Labcorp Genetics (formerly Invitae)
  • congenital myasthenic syndrome
    Inheritance: AR Classification: STRONG Submitted by: Genomics England PanelApp
  • epidermolysis bullosa simplex 5B, with muscular dystrophy
    Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: PanelApp Australia, Orphanet, Genomics England PanelApp
  • epidermolysis bullosa simplex 5C, with pyloric atresia
    Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
  • epidermolysis bullosa simplex with nail dystrophy
    Inheritance: AR Classification: STRONG Submitted by: PanelApp Australia
  • autosomal recessive limb-girdle muscular dystrophy
    Inheritance: AR Classification: MODERATE Submitted by: ClinGen
  • aplasia cutis congenita
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • cholestasis
    Inheritance: AR Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.85).
BP6
Variant 8-143938609-C-G is Benign according to our data. Variant chr8-143938609-C-G is described in ClinVar as Benign. ClinVar VariationId is 256171.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.387 is higher than 0.05.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_201384.3. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
PLEC
NM_201384.3
MANE Select
c.174+22G>C
intron
N/ANP_958786.1
PLEC
NM_201378.4
MANE Plus Clinical
c.132+22G>C
intron
N/ANP_958780.1
PLEC
NM_201380.4
c.585+22G>C
intron
N/ANP_958782.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
PLEC
ENST00000345136.8
TSL:1 MANE Select
c.174+22G>C
intron
N/AENSP00000344848.3
PLEC
ENST00000356346.7
TSL:1 MANE Plus Clinical
c.132+22G>C
intron
N/AENSP00000348702.3
PLEC
ENST00000322810.8
TSL:1
c.585+22G>C
intron
N/AENSP00000323856.4

Frequencies

GnomAD3 genomes
AF:
0.294
AC:
44713
AN:
152026
Hom.:
7863
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.105
Gnomad AMI
AF:
0.398
Gnomad AMR
AF:
0.298
Gnomad ASJ
AF:
0.451
Gnomad EAS
AF:
0.151
Gnomad SAS
AF:
0.344
Gnomad FIN
AF:
0.389
Gnomad MID
AF:
0.332
Gnomad NFE
AF:
0.391
Gnomad OTH
AF:
0.329
GnomAD2 exomes
AF:
0.331
AC:
82651
AN:
250004
AF XY:
0.341
show subpopulations
Gnomad AFR exome
AF:
0.0916
Gnomad AMR exome
AF:
0.233
Gnomad ASJ exome
AF:
0.459
Gnomad EAS exome
AF:
0.152
Gnomad FIN exome
AF:
0.397
Gnomad NFE exome
AF:
0.393
Gnomad OTH exome
AF:
0.372
GnomAD4 exome
AF:
0.374
AC:
545998
AN:
1458414
Hom.:
106010
Cov.:
33
AF XY:
0.375
AC XY:
271857
AN XY:
725712
show subpopulations
African (AFR)
AF:
0.0909
AC:
3039
AN:
33432
American (AMR)
AF:
0.244
AC:
10911
AN:
44718
Ashkenazi Jewish (ASJ)
AF:
0.458
AC:
11956
AN:
26110
East Asian (EAS)
AF:
0.158
AC:
6272
AN:
39690
South Asian (SAS)
AF:
0.346
AC:
29865
AN:
86198
European-Finnish (FIN)
AF:
0.390
AC:
20712
AN:
53060
Middle Eastern (MID)
AF:
0.389
AC:
2246
AN:
5768
European-Non Finnish (NFE)
AF:
0.396
AC:
438914
AN:
1109140
Other (OTH)
AF:
0.366
AC:
22083
AN:
60298
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.470
Heterozygous variant carriers
0
17176
34352
51529
68705
85881
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
13470
26940
40410
53880
67350
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.294
AC:
44715
AN:
152144
Hom.:
7864
Cov.:
33
AF XY:
0.294
AC XY:
21900
AN XY:
74376
show subpopulations
African (AFR)
AF:
0.105
AC:
4355
AN:
41512
American (AMR)
AF:
0.298
AC:
4552
AN:
15300
Ashkenazi Jewish (ASJ)
AF:
0.451
AC:
1565
AN:
3472
East Asian (EAS)
AF:
0.151
AC:
780
AN:
5174
South Asian (SAS)
AF:
0.343
AC:
1653
AN:
4824
European-Finnish (FIN)
AF:
0.389
AC:
4121
AN:
10596
Middle Eastern (MID)
AF:
0.340
AC:
100
AN:
294
European-Non Finnish (NFE)
AF:
0.391
AC:
26537
AN:
67948
Other (OTH)
AF:
0.326
AC:
690
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
1575
3149
4724
6298
7873
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
444
888
1332
1776
2220
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.285
Hom.:
1020
Bravo
AF:
0.287

ClinVar

Significance: Benign
Submissions summary: Benign:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:2
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

Jun 19, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.

Epidermolysis bullosa simplex with nail dystrophy Benign:1
Oct 25, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

not specified Benign:1
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Epidermolysis bullosa simplex 5C, with pyloric atresia Benign:1
Oct 25, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Epidermolysis bullosa simplex 5B, with muscular dystrophy Benign:1
Oct 25, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Autosomal recessive limb-girdle muscular dystrophy type 2Q Benign:1
Oct 25, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Epidermolysis bullosa simplex, Ogna type Benign:1
Oct 25, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.85
CADD
Benign
5.1
DANN
Benign
0.45
PhyloP100
0.24
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs7823393; hg19: chr8-145012777; COSMIC: COSV59615970; API